# Exo Imaging

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exo-imaging

- Industry: Medical Devices & Equipment
- Headquarters: Redwood City, US
- Website: www.exo.inc
- Total disclosed funding: $251M
- Latest round: Series C (Jul 29, 2021)
- Investors on record: 21

## About

Exo Imaging, Inc. specializes in point-of-care ultrasound (POCUS) devices, providing advanced imaging solutions that enhance diagnostic capabilities for healthcare providers in various medical environments.Founded in 2015 and headquartered in Redwood City, US, Exo Imaging, Inc. develops innovative ultrasound solutions for healthcare. The company was established by a team including Gwizzz Music, John Kokulis, Sandeep Akkaraju, and Yusuf Haque. Exo has successfully raised funding through 7 deals, with the latest being Series C, amounting to USD 185.99 mn, led by RA Capital, bringing its total funds raised to USD 185.99 mn and current valuation at USD 519.34 mn.Exo Imaging, Inc. specializes in point-of-care ultrasound (POCUS) devices, with its flagship product, the Exo Iris®, leading the market. This handheld ultrasound system integrates industry-first technology and advanced artificial intelligence (AI) to deliver high-performance imaging suitable for a variety of medical environments. The Exo Iris® is designed to facilitate immediate diagnostic capabilities at the point of care, enabling healthcare providers to scan, document, and bill patients efficiently in seconds. The company’s innovative SweepAI™ technology enhances cardiac and lung scanning capabilities by providing real-time feedback and diagnostic insights without reliance on internet connectivity. Geographically, Exo targets healthcare institutions, clinics, and medical professionals across North America and various international markets, ensuring accessibility to affordable healthcare solutions for a broad range of patients.Exo Imaging generates revenue primarily through the sale of its Exo Iris® ultrasound devices and associated services, which include educational programs and technical support. The transaction structure is primarily B2B, with sales directed toward healthcare facilities, clinics, and individual medical practitioners utilizing ultrasound technology in their practice. Pricing details for the Exo Iris® and related services have not been disclosed, but the company often provides promotional offers, such as discounts for new buyers. Additionally, Exo Imaging has engaged in strategic partnerships to enhance its distribution channels and expand its client base, with a focus on advanced AI capabilities within its devices to meet the growing demand for efficient, portable diagnostic tools in healthcare.Exo Imaging, Inc. plans to leverage recent funding to support the development of new products and expand its market presence. The company is focused on launching innovative features within the Exo Iris® and aims to enter new geographic markets, although specific locations and timelines have not been detailed. In addition, Exo Imaging has recently raised an undisclosed amount of venture funding from new investor SGInnovate, which will likely be utilized to bolster these strategic initiatives.

## Funding rounds

- Series C, Jul 29, 2021, $186M — BlackRock, Pura Vida Investments, RA Capital Management, Sands Capital Alternatives, Avidity Partners Management
- Series B, Apr 22, 2020, $26M — Intel Capital, Applied Ventures, Rising Tide, Action Potential Venture Capital, Nautilus Venture Partners, BOLD Capital Partners, OSF HealthCare, Sony Innovation Fund, Qstar Capital, Wanxiang Healthcare Investments, Creative Ventures, Longevity Vision Holding, TDK Ventures, Solasta Ventures, Fiscus Ventures
- Series B, May 17, 2019, $32M — Intel Capital, Applied Ventures, Magnetar Capital, Rising Tide, Nautilus Venture Partners, BOLD Capital Partners, OSF HealthCare, Sony Innovation Fund, Wanxiang Healthcare Investments, Creative Ventures, Longevity Vision Holding
- Series A, Oct 10, 2017, $6.5M — Applied Ventures, Rising Tide, BOLD Capital Partners

## Investors

- Applied Ventures (https://capitalatlas.ai/funds/applied-ventures) — Series A, Series B
- Rising Tide — Series A, Series B
- BOLD Capital Partners (https://capitalatlas.ai/funds/bold-capital-partners) — Series A, Series B
- Intel Capital (https://capitalatlas.ai/funds/intel-capital) — Series B
- Magnetar Capital (https://capitalatlas.ai/funds/magnetar-capital) — Series B
- Nautilus Venture Partners (https://capitalatlas.ai/funds/nautilus-venture-partners) — Series B
- OSF HealthCare — Series B
- Sony Innovation Fund (https://capitalatlas.ai/funds/sony-innovation-fund) — Series B
- Wanxiang Healthcare Investments (https://capitalatlas.ai/funds/wanxiang-healthcare-investments) — Series B
- Creative Ventures (https://capitalatlas.ai/funds/creative-ventures) — Series B
- Longevity Vision Holding (https://capitalatlas.ai/funds/longevity-vision-holding) — Series B
- Action Potential Venture Capital (https://capitalatlas.ai/funds/action-potential-venture-capital) — Series B
- Qstar Capital (https://capitalatlas.ai/funds/qstar-capital) — Series B
- TDK Ventures (https://capitalatlas.ai/funds/tdk-ventures) — Series B
- Solasta Ventures (https://capitalatlas.ai/funds/solasta-ventures) — Series B
- Fiscus Ventures — Series B
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series C
- Pura Vida Investments (https://capitalatlas.ai/funds/pura-vida-investments) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series C
- Avidity Partners Management — Series C